1 / 6
Laboratory Research Material
CJC-1295 NO DAC
5 mg per vial · Lyophilized powder
Laboratory Research Material
CJC-1295 NO DAC 5 mg per vial
$39.99
- Compound
- CJC-1295 NO DAC
- Amount per vial
- 5 mg
- Form
- Lyophilized powder
- Packaging
- 1 × 3 mL vial, boxed
- Shipping
- FedEx 2DayShips from the U.S. Estimated arrival2 business days after dispatchWeekday dispatch · 4 p.m. ET cutoff
Delivery details
Estimated for in-stock orders using FedEx 2Day. Weekends and FedEx closures are excluded. Holiday pickups, destination and carrier delays can affect arrival. Alaska and Hawaii may take longer.
Free U.S. shipping on orders $199+
Important
Research Use Notice
All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Do not administer these products to humans or animals.
Product Documentation
Details, specifications, and documents
Description
CJC-1295 NO DAC 5 mg
Buy CJC-1295 NO DAC 5 mg for laboratory research, supplied as lyophilized powder in one boxed 3 mL vial.
This is the standard 29-amino-acid modified GRF(1-29) peptide without a DAC attachment. Its reference CAS number is 446036-97-1. It is distinct from CJC-1295 with DAC and from a blend containing a second peptide.
NO DAC and DAC are different specifications
DAC means drug affinity complex. The NO DAC designation distinguishes this material from the albumin-binding modification associated with CJC-1295 DAC. The standard sequence has D-alanine at position 2, glutamine at position 8, alanine at position 15 and leucine at position 27, with an amidated C-terminus. These details distinguish it from unmodified GRF(1-29).
CJC-1295 DAC is listed separately. The CJC-1295 NO DAC + Ipamorelin blend contains two components, so its total vial amount is not the amount of CJC alone.
Read the study’s chemical construct
Jetté and colleagues investigated modified human growth hormone-releasing factor constructs conjugated to albumin. The conjugates retained activity in cultured rat pituitary-cell assays, and the selected CJC-1295 construct showed extended circulation in rats.
The albumin-reactive modification was part of that experiment. Its persistence findings therefore should not be assigned to a NO DAC preparation. A shared GHRH-related name does not establish that two supplied materials have the same analytical or biological behavior.
Amount, container and documentation
The 5 mg amount refers to labeled material; 3 mL describes the vial’s capacity. The product is supplied dry, so the container size is not an included solution volume. Use the material specification and laboratory method to choose preparation conditions.
COA & Documents provides the available reports and product files. Match the product and lot, then distinguish identity findings, chromatographic purity and measured content. For storage or handling, use instructions that apply to the supplied form; a reference paper does not establish this lot’s shelf life.
Additional information
| CAS No. | 446036-97-1 |
|---|---|
| Purity | ≥99% |
| Applications | In-vitro assay research, compound characterization, analytical method development |
| Synthesis | Solid-phase synthesis |
| Format | Lyophilized powder |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
COA & Documents
Independent lot testing
CJC-1295 NO DAC 5mg Certificate of Analysis
This product has featured batch-specific third-party laboratory documentation. The Pure Lab Peptides summary presents selected source-report fields in a consistent format; the linked original laboratory report controls if any information differs.
- Lot number
- 29563
- Report number
- IF-824-QSA-TR006-2026-127-13
- Date tested
- March 2, 2026
- Reported purity
- 99.7%
- Labeled content
- 5 mg
Product documents
Product information and laboratory resources. For lot-specific results, use the COA above.
Product & packaging information
Labeled amount, physical form and packaging for CJC-1295 NO DAC 5mg.
Revision 0.4 · 2026-10-05Download PDFLaboratory handling guide
General guidance for applicable lyophilized research materials. Not a product-specific SDS.
Revision 1.0 · 2026-09-22Download PDFGeneral guides & resources
Reading a COA & Verifying Your Lot
PDF · Revision 1.0Receiving, Storage & Traceability Record
PDF · Revision 1.0Research Use & Documentation Scope
PDF · Revision 1.0
Need Assistance?
Questions about product documentation?
Contact our support team for help with product records, lot information, orders or certificate verification.